Cathepsin K

06/11/2015 - "Inhibition of Cathepsin K: A Novel and Promising Treatment for Osteoporosis."
08/01/2014 - "ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. "
01/01/2014 - "ONO-5334, a selective inhibitor of cathepsin K, is a potential new treatment for osteoporosis. "
08/01/2009 - "Inhibition of cathepsin K (CatK) is a potential new treatment for osteoporosis. "
08/01/2014 - "Modeling and simulation of bone mineral density response from a phase 2 study of ONO-5334, a new cathepsin K inhibitor, to support dose selection in osteoporosis."

07/01/2014 - "Effects of novel cathepsin K inhibitor ONO-5334 on bone resorption markers: a study of four sustained release formulations with different pharmacokinetic patterns."
02/01/2013 - "In this study, we applied a novel gene therapeutic approach using recombinant adeno-associated virus (AAV)-mediated RNAi knockdown of Cathepsin K (Ctsk) gene expression, to target osteoclasts and periapical bone resorption in a mouse model. "
04/01/2009 - "The present study describes the intracellular mechanisms by which overexpression of cathepsin K in osteoclasts results in enhanced bone resorption. "
07/01/2006 - "In a preliminary study, treatment of osteoclasts containing long bone cells with the water extract of UD bark prevented the intracellular maturation of cathepsin K (cat K), and thus, it was considered that UD is a pro-drug of a potent bone-resorption inhibitor. "
06/01/2005 - "Despite the age-related increase in bone resorption, this study shows lower cathepsin K values in elderly women and men than in younger subjects. "

06/01/2011 - "Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study."
03/01/2014 - "The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study."
12/01/2015 - "Therefore, SI-591, a novel cathepsin K inhibitor, could be a promising agent for the treatment of postmenopausal osteoporosis. "
02/01/2014 - "Cathepsin K inhibitors, such as ONO-5334, are being developed for the treatment of postmenopausal osteoporosis. "
12/01/2009 - "Because excessive bone remodeling is a key element in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders, cathepsin K is a potential target for therapeutic intervention. "

05/22/2015 - "We reveal that genetic deletion of cathepsin K (Ctsk) caused a radical reduction in inflammation and bone erosion within RA joint capsules and periodontal lesions, a drastic decrease in immune-cell infiltration, and a significant reduction in osteoclasts, macrophages, dendritic and T-cells. "
04/01/2013 - "Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice."
02/01/2013 - "Our study shows that AAV-RNAi silencing of Cathepsin K in periapical tissues can significantly reduce endodontic disease development, bone destruction, and inflammation in the periapical lesion. "
09/01/2015 - "Cathepsin K Inhibitor Regulates Inflammation and Bone Destruction in Experimentally Induced Rat Periapical Lesions."
04/01/2013 - "Here, the authors address the relevance of cathepsin K in the intestinal immune response during chronic intestinal inflammation. "

03/01/2011 - "The aim of this study is to examine stromal expression of cathepsin K in skin tumors. "
12/01/2015 - "Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression."
06/01/2013 - "Immunohistochemically, tumor cells show nuclear immunolabeling for TFEB and usually express Cathepsin-K in the cytoplasm. "
06/01/2013 - "FISH-positive cases showed negative or equivocal immunoreactivity for TFE3 or cathepsin K in 7 and 10 tumors, respectively (both=3). "
06/01/2013 - "Seventeen cases showed TFE3 rearrangement associated with Xp11.2 translocation by FISH, including all 13 tumors with moderate or strong TFE3 (n=10) or cathepsin K (n=7) immunoreactivity. "